image: A) We used advanced single cell analysis to examine B cells in the blood of human mRNA vaccine recipients and COVID-19 patients. B) Several new types of B-cells were discovered, notable division of activated B-cells into classical and atypical subgroups. C) Classical memory is the most common type of B cell in healthy donors. D) Activated atypical B-cells are the most common form of SARS-CoV-2 specific B cell in the blood following mRNA vaccination or COID-19.
Credit: Created with BioRender.com
Osaka, Japan – Vaccines work by equipping our immune systems to fight an invading virus. When we get vaccinated against COVID-19, specialized immune cells known as B cells learn to recognize the virus. If we subsequently get infected with COVID, these B cells will quickly manufacture antibodies to attack and destroy the virus. However, because the mRNA vaccines developed for COVID-19 are so new, researchers did not know exactly which B cells were called into action.
Now, in a study published in Nature Communications, a team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination.
“Several different types of B cells can be activated after vaccination, but it was not clear which B cells responded to the COVID-19 mRNA vaccine,” says lead author David Priest. “We found that blood from people who were vaccinated against COVID-19 contained activated atypical B cells. These B cells are the main responders to the vaccine because they are highly correlated with the serum antibody response against the COVID-19 virus.”
The team used a method called mass cytometry to examine and identify individual cells within the two known groups of B cells. These groups are classical B cells, which are common in human blood, and non-classical B cells. The newly discovered activated atypical cells fall into the non-classical group. The team also found these cells in the blood of patients who were infected with COVID-19.
“Activated atypical B cells provide a new way to assess how well people respond to COVID-19 vaccination. They also give us a new understanding of the underlying biology of mRNA vaccination,” explains senior author James Wing. “Now that we know these B cells are the primary responders to mRNA vaccines, we can work toward targeting them in future vaccine designs.”
With the help of this study, researchers may be able to develop improved updates to current COVID-19 vaccines as well as better candidate vaccines to help prevent future pandemics.
###
The article, “Atypical and non-classical CD45RBlo memory B cells are the majority of circulating SARSCoV-2 specific B cells following mRNA vaccination or COVID-19,” was published in Nature Communications at DOI: https://doi.org/10.1038/s41467-024-50997-4
About Osaka University
Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan's leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world. Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation.
Website: https://resou.osaka-u.ac.jp/en
Journal
Nature Communications
Method of Research
Experimental study
Subject of Research
People
Article Title
Atypical and non-classical CD45RBlo memory B-cells are the majority of circulating SARS-CoV-2 specific B-cells following mRNA vaccination or COVID-19.
Article Publication Date
9-Aug-2024